Section 1. Purpose.
The purpose of this rule is to establish a process for
independent external reviews of adverse benefit determinations regarding health
benefits that are eligible for independent external review by law.
Section 2. Authority.
The Commissioner of Financial Regulation has the authority to
issue this rule under
8 V.S.A.
§§
15,
4089a and
4089f.
Section 3. Applicability and Scope.
(A) This rule shall apply to every
comprehensive major medical health benefit plan subject to the Department's
jurisdiction, and the definitions of "medically necessary care", "experimental
or investigational", and "medically appropriate off-label use of a drug" in the
contracts, policies, certificates and other forms related to such plans shall
be as defined in this rule.
(B)
This rule shall not apply to any health benefit plan that is not a
comprehensive major medical health benefit plan subject to the Department's
jurisdiction and shall not apply to one that provides coverage only for a
specified disease, specified accident or accident- only coverage, credit,
dental, disability income, hospital indemnity, long-term care insurance, vision
care or any other limited supplemental benefit, Medicare supplement, Medicare
Advantage, coverage provided by the Vermont Medicaid program or Medicaid
benefits provided through a contracted health plan, or to health care services
provided to inmates by the Department of Corrections.
(C) Health Benefit Plans not subject to the
Department's jurisdiction may voluntarily agree to utilize the independent
external review process, however, the definitions of "medically necessary
care", "experimental or investigational", and "medically appropriate off-label
use of a drug" as defined in this rule, shall not apply to these
plans.
(D) If any provisions of any
such contract, policy, certificate or other forms conflict with provisions of
this rule, the Department and the independent review organization shall use
whichever provision is more beneficial to the insured.
Section 4. Definitions.
(A) "Adverse benefit determination" means a
denial, reduction, modification or termination of, or a failure to provide or
make payment (in whole or in part) for, a benefit, including but not limited
to:
1. a denial, reduction, termination or
failure to provide or make payment that is based on a determination of a
participant's or beneficiary's eligibility to participate in a health benefit
plan;
2. a denial, reduction,
modification or termination of, or a failure to provide or make payment (in
whole or in part) for, a benefit resulting from the application of any
utilization review;
3. a failure to
cover an item or service for which benefits are otherwise provided because it
is determined to be experimental or investigational or not medically necessary
or appropriate; and
(B)
"Appealable decision" means an adverse benefit determination made by a health
insurer to deny, reduce or terminate health care coverage, payment or a
preferred level of payment for a health care service; where; the insured has
exhausted all internal grievances required by law relating to the decision; and
the decision is based on one of the following reasons:
1. The health care service is a covered
benefit that the health insurer has determined to be not medically
necessary.
2. A limitation is
placed on the selection of a health care provider that is claimed by the
insured to be inconsistent with limits imposed by the health benefit plan and
any applicable laws and regulations.
3. The health care treatment has been
determined to be experimental or investigational or an off-label use of a
drug.
4. The health care service
involves a medically-based decision that a condition is preexisting.
5. The decision involves an adverse
determination related to surprise medical billing, as established under Section
2799A-1 or 2799A-2 of the Public Health Service Act (42 U.S.C. §
300gg-111 or
300gg-112), including with respect
to whether an item or service that is the subject of the adverse determination
is an item or service to which Section 2799A-1 or 2799A-2 of the Public Health
Service Act, or both, applies.
(C) "Commissioner" means the Commissioner of
Financial Regulation or his or her designee.
(D) "Conflict of interest" means a material
professional, familial or financial relationship with any of the following
persons:
1. The insured (and any related
parties to the insured) who has filed the independent external
review.
2. Any health care provider
responsible for the experimental or investigational treatment.
3. The health insurer, mental health review
agent, administrator of the health benefit plan or any other person or entity
that issued the decision that is the subject of the independent external
review.
4. Any officer, director,
or management employee of the health benefit plan or any other person or entity
that issued the decision that is the subject of the independent external
review.
5. The insured's treating
provider or the provider's medical group (and any related parties to the
treating provider or members of the medical group) recommending the health care
service or treatment that is the subject of the independent external
review.
6. The health care
provider, facility or other entity at or by which the service or treatment that
is the subject of the independent external review would be provided.
7. Entities involved in the development or
manufacture of the principal drug, device, procedure or other therapy that is
the subject of the independent external review.
(E) "Department" means the Department of
Financial Regulation.
(F)
"Emergency medical condition" shall have the same meaning as in
42 U.S.C. §
300gg-111(a)(3)(B).
(G) "Emergency services" shall have the same
meaning as in 42 U.S.C.
§
300gg-111(a)(3)(C).
(H) "Experimental or investigational
services" means health care items or services that are:
1. not generally accepted by informed health
care providers in the United States as effective in treating the condition,
illness or diagnosis for which their use is proposed, or are;
2. not proven by medical or scientific
evidence to be effective in treating the condition, illness or diagnosis for
which their use is proposed.
(I) "Health benefit plan" means a policy,
contract, certificate or agreement entered into, offered or issued by a health
insurer to provide, deliver, arrange for, pay for, or reimburse any of the
costs of health care services.
(J)
"Health care provider" means a person, partnership, corporation or other legal
business entity licensed or certified or authorized by law to provide
professional health care services to an individual during that individual's
health care, treatment or confinement.
(K) "Health care services" or "services"
means items or services for the diagnosis, prevention, treatment, cure or
relief of a health condition, illness, injury or disease.
(L) "Health insurer" or "insurer" shall have
the same meaning as in
18 V.S.A.
§
9402(8). For purposes
of this rule, "health insurer" or "insurer" also means a mental health review
agent or any other agent or delegate of a health benefit plan that makes or
issues appealable decisions as defined by this rule.
(M) "Independent review organization" or
"IRO" means an organization under contract with the Department under Section 8
of this rule to undertake independent external reviews of appealable decisions
pursuant to
8 V.S.A.
§
4089f.
(N) "Insured" means the beneficiary of a
health benefit plan subject to this Rule, including the subscriber and all
others covered under the plan. For purposes of this Rule, "insured" shall
include any provider or other person acting on behalf of an insured with the
insured's HIPAA compliant authorization.
(O) "Medical or scientific evidence" means
the following sources:
1. Peer-reviewed
scientific studies published in or accepted for publication by medical journals
that meet nationally recognized requirements for scientific manuscripts and
that submit most of their published articles for review by experts who are not
part of the editorial staff.
2.
Peer-reviewed literature, biomedical compendia and other medical literature
that meet the criteria of the National Institutes of Health's National Library
of Medicine for indexing in, Excerpta Medica (EMBASE), Medline, Pubmed Medline,
resources from the Cochrane Library, HSTAT, and the National Guideline
Clearinghouse.
3. Medical journals
recognized by the federal Secretary of Health and Human Services, under Section
1861(t)(2) of the federal Social Security Act.
4. The following standard reference
compendia: the American Hospital Formulary Service- Drug Information (AHFS Drug
Information), the American Dental Association Accepted Dental Therapeutics and
Monograph Series on Dental Materials and Therapeutics, The United States
Pharmacopeia, The National Formulary and the USP-DI.
5. Findings, studies or research conducted by
or under the auspices of federal government agencies and nationally recognized
federal research institutes, including the Agency for Health Care Research and
Quality, National Institutes of Health, National Cancer Institute, National
Academy of Sciences, Centers for Medicare and Medicaid Services, and any
national board recognized by the National Institutes of Health for the purpose
of evaluating the medical value of health services.
6. Peer-reviewed abstracts accepted for
presentation at major medical association meetings.
(P) "Medically appropriate off-label use of a
drug" means the use of a drug, pursuant to a valid prescription by a health
care provider, for other than the particular condition(s) for which approval
was given by the U.S. Food and Drug Administration in circumstances in which
the medically appropriate off-label use is reasonably calculated to restore or
maintain the member's health, prevent deterioration of or palliate the member's
condition, prevent the reasonably likely onset of a health problem or detect an
incipient problem; and that is informed by generally accepted medical or
scientific evidence and consistent with generally accepted practice parameters
as recognized by health care professions in the same specialties as typically
provide the procedure or treatment, or diagnose or manage the medical
condition.
(Q) "Medically-necessary
care" means health care services, including diagnostic testing, preventive
services and aftercare that are appropriate, in terms of type, amount,
frequency, level, setting, and duration to the member's diagnosis or condition.
Medically-necessary care must be informed by generally accepted medical or
scientific evidence and consistent with generally accepted practice parameters
as recognized by health care professions in the same specialties as typically
provide the procedure or treatment, or diagnose or manage the medical
condition, and must be informed by the unique needs of each individual patient
and each presenting situation, and
1. help
restore or maintain the member's health; or
2. prevent deterioration of or palliate the
member's condition; or
3. prevent
the reasonably likely onset of a health problem or detect an incipient
problem.
(R) "Off-label
use of a drug" means use of a drug for other than the particular condition for
which approval was given by the U.S. Food and Drug Administration.
(S) "Relevant document, record or other
information" means, for the purposes of Section (5)(H)a. of this Rule that a
document, record or other information shall be considered relevant if such
document, record or other information was relied upon in making the benefit
determination or the determination of a grievance, or was submitted, considered
or generated in the course of making the benefit determination or the
determination of a grievance, without regard to whether such document, record
or other information was relied upon in making the benefit determination or the
determination of a grievance.
(T)
"Urgent care" means those health care services that are necessary to treat a
condition or illness of an individual that if not provided promptly (within
twenty-four (24) hours or a time frame consistent with the medical exigencies
of the case) presents a serious risk of harm.
Section 5. Requests for Independent External
Review.
(A) An insured may obtain independent
external review of an appealable decision using the procedures established in
this section. Exhaustion of the internal grievance process is not required when
the insurer has waived the internal grievance process or has been deemed to
have waived the internal grievance process by failing to adhere to grievance
process time requirements. The right to independent external review is
contingent on the insured's exhaustion of the health insurer's first level
internal grievance process. The health insurer shall provide insureds with a
Department-approved notice of Vermont appeal rights with each notification of
adverse benefit determination.
(B)
To the extent that Insurers prepare any of the following documents: summary
plan description, policy, certificate, and/or membership booklet, Insurers
shall include a description of the external review process.
(C) Neither the right to obtain independent
external review nor any resulting decision by an IRO shall be construed to
change the terms of coverage under a health benefit plan.
(D) To initiate an independent external
review, the insured shall file a written request on a form specified by the
Department, which shall include a release executed by the insured for all
medical records pertinent to the independent external review, identification of
the insurer by whom the insured is covered and which made the decision at
issue, and a copy of the notice of the final grievance decision. The written
request must be made within one hundred twenty (120) days or 4 months whichever
is longer from any of the following to occur:
1. receipt of written documentation of the
health benefits plan's final grievance decision and notice of appeal
rights,
2. the insurer having
waived the required grievance process, or
3. the insurer is deemed to have waived the
grievance process by failing to adhere to grievance process time
requirements.
(E) A
request for independent external review shall be considered timely if the
Department has received an oral or written inquiry complaint or request for
review pertaining to the matter in dispute at any time prior to the deadline
and the request for independent external review is confirmed in writing on the
Department-approved form within ten (10) working days.
(F) An insured may initiate an expedited
independent external review simultaneously when applying for an urgent internal
grievance. The request for an expedited independent external review and the
request for an urgent internal grievance must be filed within the time frames
for requesting an urgent internal grievance set forth in rule H-2009-03. The
written request must include the information required in Section
5(D) with the
exception of a copy of the notice of the final grievance decision.
(G) An insured shall be entitled to
assistance from the Department if the insured is unable to file a written
request for review under this section. The Department shall not refuse to
accept a request for an independent external review or determine that an
independent external review has not met the requirements of this rule for the
sole reason that the request for an independent external review is not on the
Department-approved form.
(H) The
application fee is twenty-five ($ 25.00) dollars for independent external
review of an appealable decision. The annual limit on filing fees for any
insured shall not exceed seventy-five ($ 75.00) dollars. Upon determination of
financial hardship, the Commissioner may in his or her discretion reduce or
waive the fee. In determining whether financial hardship is present, the
Commissioner shall take into consideration the reasons for the insured's
request. The Commissioner shall waive or reduce the fee for persons who
demonstrate they are eligible for a state- or federally-based assistance
program such as food stamps, TANF (Temporary Aid to Needy Families), General
Assistance, Medicaid, SSI, fuel assistance or unemployment assistance. Upon the
appealable decision being overturned by the IRO, the $ 25.00 fee if paid shall
be refunded to the insured.
(I)
Within five (5) business days of receiving the request, the Department shall
accept the request for an independent external review if it determines that:
1. the individual is or was an insured of the
health insurer;
2. the service that
is the subject of the independent external review reasonably appears to be a
covered service under the benefits provided by contract to the
insured;
3. the independent
external review involves an appealable decision (as defined in this
rule);
4. the insured has exhausted
the health insurer's required internal grievance process as required by law;
and
5. the insured has provided all
information required by the Department to ensure compliance with this
Rule.
(J) If the
materials submitted by the insured are not complete, the Department shall
notify the insured of what materials are incomplete and the time within which
they must be submitted.
(K) Upon
completion of its review, the Department shall notify the insured and the
health insurer and, if applicable, the mental health review agent whether the
application for independent external review has been accepted. If the
application for independent external review is accepted, the Department shall
also notify the parties of their opportunity to submit information and
supporting documentation for consideration by the applicable IRO. Such
information and documentation shall include:
1. Documentation to be submitted by the
health insurer and, if applicable, the mental health review agent: All relevant
documents, records or other information in its possession or control, including
the review criteria used in making the decision being appealed under this rule,
copies of any applicable policies or procedures, and copies of all medical
records considered by the insurer in making its initial decision and its
decisions pursuant to the internal grievance process. The health insurer and,
if applicable, the mental health review agent, shall consecutively number the
pages in its documentation and identify the total number of pages.
2. Documentation to be submitted by the
insured: All medical records and any additional information that the insured
would like to have considered by the IRO, which may include at the insured's
discretion written statements by either the insured and/or his or her health
care providers, or both, relating to the subject of the independent external
review.
(L) The
information and supporting documentation required under Section
5(H) must be
submitted to the Department within ten (10) days from the date the notice sent
under that section was received, except as follows:
1. health insurers and mental health review
agents, if applicable may request an extension of up to ten (10) days in which
to submit the information; and documentation, which shall be granted by the
Department only for good cause shown.
2. insureds may request an extension within
which to submit their information and supporting documentation for any reason,
except that the Department may set a final deadline for submission if the
insured has not submitted his or her information after having been granted
multiple extensions.
(M)
The Department shall provide copies of the information and supporting
documentation filed by the insured and the health insurer to the other and to
the IRO. Each shall have three (3) business days from receipt of the copies to
file responsive information or documentation with the Department. The
Department may grant extensions for filing responsive information on the same
bases as set forth in paragraph (I) of this subsection. Upon receiving all
supporting documentation filed by the insured and the health insurer, the
Department shall:
1. select an IRO on a
rotating basis and determine whether it is able to accept the assignment. If
the organization has a conflict of interest, does not have a reviewer available
who is knowledgeable about the procedure or treatment, or is otherwise not able
to accept the assignment, the Department shall assign the independent external
review to the next IRO on the list without a conflict that is able to accept
the assignment.
2. notify the
insured and the insurer of the specialty of the reviewer who has been assigned
by the IRO.
(N) Within 10
business days of the date of receipt by the IRO of the external appeal for
review under Section
5(H), the insured
or the health insurer may submit additional information or supporting materials
to the Department. The additional information or supporting materials shall be
sent by the Department to the other party, who shall have three (3) business
days after receipt within which to file any additional responsive information
or supporting materials. All such information shall then be sent by the
Department to the IRO for review as part of the independent external
review.
(O) When submitting new
information under Section
5(K), the insured
may request that the health insurer or mental health review agent, if
applicable, reconsider the decision being appealed based on the additional
information being provided. In addition, if the IRO to whom the independent
external review is assigned determines at any time that information it has
received as part of the independent external review was not available or not
made available to the health insurer or mental health review agent during its
internal review process, it may also request the health insurer or mental
health review agent to reconsider the decision based on the new information.
Any such request by either the insured or the IRO shall stay the review by the
IRO for no more than seven (7) days.
(P) Failure by the health insurer or mental
health review agent to submit information and documentation within the time
periods required in this section or to participate in a telephone conference,
if any, shall not delay independent external review and shall not impair the
ability of the IRO to issue a binding decision that upholds, reverses or
modifies the decision that was subject to independent external
review.
(Q) The Department in its
sole discretion may toll any time frame to promote dispute resolution at the
request of both parties.
(R)
Requests for expedited reviews shall follow the procedures contained in Section
7.
Section 6. Review by
Independent Review Organization.
(A) An IRO to
which an independent external review has been assigned by the Department shall
conduct a full review to determine whether:
1.
the health care service at issue is medically necessary;
2. the health insurer has limited the
insured's selection of a health care provider in a manner inconsistent with any
limits imposed by the insurance contract and any applicable laws and
rules;
3. the proposed health care
treatment is experimental or investigational or a medically- appropriate
off-label use of a drug, as those terms are defined in this rule;
4. the service as to which coverage is being
denied relates to a preexisting condition for which no coverage is available
under the insurance contract;
5.
the decision involves an adverse determination related to surprise medical
billing, as established under Section 2799A-1 or 2799A-2 of the Public Health
Service Act (42 U.S.C.
§
300gg-111 or
300gg-112).
(B) The IRO shall review all of the materials
included in the independent external review documentation provided by the
Department or obtained as a result of a telephone conference, if any, including
all pertinent medical records, consulting provider reports and other documents
submitted by the parties, and any statement filed by the insured or his or her
treating providers. The IRO's final decision shall be based on objective
clinical evidence, and shall consider any applicable generally-accepted
practice guidelines developed by the federal government, national or
professional medical societies, boards and associations, and clinical protocols
or practice guidelines developed by the health insurer or mental health review
agent The IRO is not bound by the insurer's or mental health review agent's
clinical protocols or practice guidelines, and it shall give clinical data
reported by the treating provider equal or greater weight than the protocols or
practice guidelines used by the health insurer or mental health review
agent.
(C) In the course of
reviewing the independent external review, the IRO may request that the
Department obtain any additional information or approve the addition of a
reviewer(s) with special expertise if the IRO and the Department agree that the
information or additional reviewer is necessary or relevant to the independent
external review. The Department will notify the insured and the insurer of any
such request for additional information or the addition of another reviewer.
Upon receipt of additional information, the Department shall provide copies to
the insured and the insurer. Each shall have 3 business days from receipt of
copies of the additional information to submit additional responsive
information or to dispute the need for an additional reviewer.
(D) If the insured has requested when filing
the request for independent external review or materials to be considered
during the independent external review, or the insurer has requested after
notification of the request for an independent external review, the IRO shall
meet by teleconference with the insured, the insured's representative and/or
his or her treating provider, and a representative(s) of the health insurer, to
review and discuss the clinical evidence in the independent external
review.
(E) Except as provided in
Section 7(C) of this rule, the IRO shall complete its review and forward its
determination to the Department as soon as possible in accordance with the
medical exigencies of the case, which (except as provided in this subsection)
shall not exceed thirty (30) days from receipt of all of the documentation. The
decision shall be in writing and shall include the clinical rationale for the
IRO's determination. The IRO may request an extension of time from the
Department within which to complete its review as may be necessary due to
circumstances beyond its control, including but not limited to the receipt of
additional information after the independent external review has been forwarded
for review as set forth in Section
5(K), or the
inability to timely schedule a telephone conference due to the unavailability
of the applicant, the applicant's representative, any of the applicant's
treating provider(s) or the insurer's representative(s).
(F) Upon receipt of the IRO's determination,
the Department shall review it to ensure that it does not change the terms of
coverage under the insured's health benefit plan, and then issue the
determination to the health insurer, mental health review agent, if
appropriate, and the insured. The IRO's determination shall be binding on the
insurer and the insured except to the extent either the insurer or insured has
other remedies under applicable federal or Vermont laws.
(G) If the Department finds that the IRO's
determination changes the terms of the insured's health benefit plan, it shall
immediately return the determination to the IRO for revision.
(H) The Department may use all enforcement
powers granted to it under Titles 8 and 18 of the Vermont Statutes Annotated to
ensure compliance by health insurers and mental health review agents with the
requirements of this rule and any other applicable law or rule.
(I) No health insurer shall retaliate against
an insured or provider for any activity related to independent external
review.
(J) The determinations of
an IRO on individual cases shall have no precedential value as to any other
independent external review filed with the Department.
(K) The insured has the right to ask a health
insurer to review a request for the same or similar services as to which an IRO
has upheld an earlier denial if, since the IRO's decision was made, the
insured's medical condition has changed or the scientific or medical evidence
as to the effectiveness of a proposed treatment has changed. The insured must
exhaust the insurer's internal utilization management and grievance
processes.
Section 7.
Expedited Reviews.
(A) Independent external
reviews that the Department determines should be expedited, that have resulted
from grievances that were required by law to be expedited, or that have been
designated "emergency" or "urgent" by the insured or the insured's treating
health care provider shall be expedited, as follows:
1. Upon receipt of an oral or written request
for independent external review that is the result of a grievance that has been
designated as expedited, or that the Department in its sole discretion
determines shall be expedited, and that meets the requirements for
reviewability set forth in Section
5(F) of this
rule, the Department shall immediately accept the request for reviews related
to emergency or urgent services if the insured completes and submits an
application form and filing fee, if applicable, as soon thereafter as
possible.
2. Upon acceptance of the
request for expedited independent external review, the Department will
immediately notify the health insurer and the insured by the most expeditious
means available, including telephone, fax or e-mail, of their right to submit
information and supporting documentation under Section
5(H). Such
information must be submitted to the Department in a time frame consistent with
the medical exigencies of the case but in no event later than twenty-four (24)
hours after the acceptance of the request.
3. Immediately upon receipt of the supporting
information and documentation from the insured and the insurer, but in no event
more than twenty-four (24) hours after accepting the request for expedited
review, the Department shall assign the independent external review to an IRO
for clinical review as provided in Section
6 5(F) of this rule. The IRO shall
complete its review and make a determination as soon as possible consistent
with the medical exigencies of the case, but in no event more than three (3)
days after receipt of the request for an independent external review, unless
upon further review it determines that the appeal does not involve emergency or
urgently needed services, in which case the deadline for review shall be as
contained in 6(E).
4. If the
expedited independent external review relates to services currently being
provided to an insured in a health care facility or other previously approved
course of treatment, and the request for expedited independent external review
is made within twenty-four hours of the receipt by the insured of (i) the final
grievance decision and (ii) the notice of appeal rights, whichever shall be
later received, and the expedited external review is conducted in accordance
with the time frames specified by law, the services shall be continued by the
insurer without liability to the insured until:
a) the independent external review decision
is issued, and
b) the insurer has
authorized coverage for a medically safe and appropriate discharge or
transition plan developed after consultation with the member's treating
physician or the treating health care provider's designee.
5. When the expedited independent external
review relates to services not currently being provided to an insured in a
health care facility or other course of treatment and those services by
contract require prior authorization from the insurer before being rendered,
and the IRO reasonably believes that the delay caused by the review may cause
significant harm to the insured and so notifies the Department, the Department
shall order the health insurer to provide coverage for the contested services
pending the final determination of the appeal independent external review. If
the insurer's denial is upheld by the IRO, the insured will be responsible for
reimbursing the insurer for the costs of such services paid for while the
appeal was pending.
6. Health
insurers and mental health review agents shall have qualified and informed
personnel available twenty-four (24) hours a day, seven (7) days per week, who
can respond to Department requests and assist the Department and/or IRO in
assessing and processing potential cases and cases accepted for expedited
review. Health insurers and mental health review agents shall provide the
Department with updated contact information for such personnel annually and
prior to any changes and shall ensure that all of their personnel are trained
to facilitate such communication with the Department if requested.
Section 8. Independent
Review Organizations
(A) The Department shall
from time to time enter into contracts with as many IROs as it deems necessary
to conduct the independent external review requests provided for in this Rule.
The contracts shall set forth all terms that the Department deems necessary to
ensure a full, fair and timely review of independent external reviews.
Selection of the IROs shall include review of proposals with regard to at least
the following:
1. proposed scope of
services;
2. fee structure and
total estimated costs of reviews;
3. number and qualifications of reviewers,
who shall include health care providers credentialed with respect to the health
care service under review;
4.
procedures to ensure the confidentiality of the independent external reviews,
including identifiable health care information used in reviewing the
independent external reviews;
5.
procedures to ensure the neutrality of reviewers;
6. administrative and operational policies
and procedures; and
7. procedures
to ensure that no conflict of interest exists among the organization and its
reviewers and the health insurer or insured whose case is under
review.
8. Evidence of
accreditation by at least one nationally recognized private accrediting
organization including, but not limited to, URAC or NCQA.
Section 9. External Review
Reporting Requirements.
(A) An IRO assigned
pursuant to Section
6 or 7 of this rule to conduct an
external review shall maintain written records in the aggregate for Vermont and
by insurer on all requests for external review for which it conducted an
external review during a calendar year and, upon request, submit a report to
the Commissioner, as required under paragraph (B).
(B) The report shall include in the aggregate
for Vermont, and for each insurer:
1. the
total number of requests for independent external review;
2. the number of requests for independent
external review resolved;
3. the
number resolved upholding the adverse determination or final adverse
determination and the number resolved reversing the adverse determination or
final adverse determination;
4. the
average length of time for resolution;
5. a summary of the types of coverages or
cases for which an external review was sought, as provided in the format
required by the Commissioner;
6.
the number of external reviews pursuant to Section
5(L) of this rule
that were terminated as the result of a reconsideration by the insurer of its
adverse determination or final adverse determination after the receipt of
additional information from the covered person or the covered person's
authorized representative; and
(C) The IRO shall retain the written records
required pursuant to this subsection for at least three (3) years, and make
item available at no cost to the Department.
(D) Each insurer shall maintain at no cost to
the Department, written records in the aggregate by State and for each type of
health benefit plan offered by the insurer on all requests for independent
external review that the insurer receives notices of from the Commissioner
pursuant to this rule.
(E) Each
insurer required to maintain written records on all requests for external
review pursuant to paragraph (1) shall submit to the Commissioner, upon
request, a report in the format specified by the Commissioner.
(F) The report shall include in the
aggregate, for Vermont, and by type of health benefit plan:
1. the total number of requests for external
review;
2. from the total number of
requests for external review reported under subparagraph (1) of this paragraph,
the number of requests determined eligible for a full external review;
and
3. any other information the
Commissioner may request or require.
(G) The insurer shall retain the written
records required pursuant to this subsection for at least three (3)
years.
Section 1 0. Costs
of Independent External Reviews.
The Department shall notify the health insurer of the
reasonable and necessary cost of an independent external review. The costs may
vary depending on the type of review and the IRO assigned. The costs shall
include but not be limited to the fees of the IRO, reasonable copying expenses,
mail and delivery fees and any other expense related to the review by an IRO's
review.
The insurer shall pay the costs of the independent external
review to the Department within thirty (30) days of such notification.
Section 11. Confidentiality.
All documents and records relating to independent external
reviews filed under this rule, including but not limited to independent
external review forms, supporting information and documentation filed by the
insured, by the health insurer, mental health review agent, or any materials
prepared by the Department for the use of an IRO, and the IRO's determination,
are confidential and exempt from public disclosure under
1 V.S.A.
§
316. Health insurers, mental health
review agents and IROs shall take appropriate measures to protect the
confidentiality and security of all communications, records, procedures and
meetings related to independent external reviews.
Section 12. Severability.
If a court holds any provision of this rule invalid in any
circumstance, this shall not affect any other provision or circumstance.
Section 13. Effective Date.
This revised rule shall take effect 15 days after
adoption.